title: Gemcitabine in the treatment of relapsed and refractory Hodgkin's disease.
abstract: BACKGROUND
  Patients with refractory Hodgkin's disease or relapsing after high-dose therapy and autografting have a poor prognosis. Here, we present our experiences with gemcitabine in this setting.
  
  
  METHODS
  We treated 14 patients with relapsed or refractory Hodgkin's disease with gemcitabine. The treatment was given on a compassionate use basis, off-label and not according to a study protocol. Patients were 17-46 years of age. 1 patient had stage IA disease, 2 patients had stage IIIB disease and 11 patients had stage IVB disease. 9 patients had received radiotherapy. 8 patients had been autografted and 1 patient auto- and allografted. Gemcitabine was administered at a starting dose of 1 g/m(2) on days 1 and 8 every 3 weeks in combination with steroids.
  
  
  RESULTS
  The median follow-up period was 10 months. Hematological toxicity grade 3-4 occurred in 12 patients leading to dose reductions. 1 patient died of neutropenic sepsis. No other non-hematological toxicities were observed. The response rate was 64% with 6 patients achieving complete remission (CR) and 3 patients partial remission (PR). The median time to treatment failure was 9 months, and survival was 11 months. Responses were seen in previously transplanted patients and in patients refractory to previous treatment. The so far longest responder has been in CR for over 68 months.
  
  
  CONCLUSIONS
  Gemcitabine is an effective treatment for Hodgkin's disease. Heavily pretreated patients often require dose reductions.
authors.affiliation: Division of Hematology, Department of Internal Medicine, University Hospital Center Rebro and Medical School, Zagreb, Croatia. aurer@mef.hr
authors.forename: Igor
authors.initials: I
authors.lastname: Aurer
authors.forename: Ivo
authors.initials: I
authors.lastname: Radman
authors.forename: Damir
authors.initials: D
authors.lastname: Nemet
authors.forename: Silva
authors.initials: S
authors.lastname: Zupancić-Salek
authors.forename: Vinko
authors.initials: V
authors.lastname: Bogdanić
authors.forename: Mirando
authors.initials: M
authors.lastname: Mrsić
authors.forename: Dubravka
authors.initials: D
authors.lastname: Sertić
authors.forename: Boris
authors.initials: B
authors.lastname: Labar
mesh_terms: D000293:Adolescent; D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects; D017523:Croatia / Q000453:epidemiology; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D018572:Disease-Free Survival; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology* / Q000517:prevention & control*; D011379:Prognosis; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D015996:Survival Rate; D017211:Treatment Failure; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine